目的: 探讨华蟾素胶囊联合索拉非尼治疗肝细胞癌患者的临床疗效及对AFP（alpha-fetoprotein,甲胎蛋白）、VEGF（vascular endothelial growth factor,血管内皮生长因子）指标的影响。方法: 选取湖南省中西医结合医院2021年6月至2024年6月就诊的126例肝细胞癌患者,选择随机数字表法分为两组。对照组（n=63）给予索拉非尼治疗,观察组（n=63）在对照组基础上给予华蟾素胶囊治疗。均治疗3个月后比较两组治疗效果。结果: 观察组患者治疗后白蛋白（serum albumin,ALB）、总胆红素（total bilirubin,TBIL）、谷草转氨酶（aspartate aminotransferase,AST）以及谷丙转氨酶（alanine aminotransferase,ALT）的水平均显著低于对照组;观察组患者治疗有效率显著高于对照组;观察组患者治疗后VEGF、AFP以及恶性肿瘤特异性生长因子（tumor-specific growth factor,TSCF）的水平均显著低于对照组;治疗后两组癌症患者生存质量测定量表（European organisation for research and treatment of cancer's core quality of life questionnaire-30,EORTC QLQ-C30）各维度评分均有所升高,但观察组患者显著高于对照组;两组不良反应发生情况比较差异无统计学意义。结论: 华蟾素胶囊与索拉非尼治疗肝细胞癌患者疗效较好,有助于改善患者肝功能指标,降低肿瘤标志物水平,提升患者生活质量,同时不会增加不良反应发生风险。
Abstract
Objective To investigate the clinical efficacy and the effect on alpha-fetoprotein (AFP) and vascular endothelial growth factor (VEGF) indexes of huazhuxin capsule combined with sorafenib in the treatment of patients with primary hepatocellular carcinoma. Methods Between June 2021 and June 2024, a total of 126 patients diagnosed with primary hepatocellular carcinoma at Hunan Provincial Hospital of Integrative Medicine were enrolled and randomized into two groups using a random number table. The control group (n=63) received sorafenib therapy, while the observation group (n=63) was administered Huachansu Capsule in addition to the sorafenib treatment received by the control group. Comparison of the two groups after 3 months of treatment in both groups. Results The observation group exhibited a notably higher therapeutic efficacy compared to the control group. Subsequent to therapy, the concentrations of serum albumin (ALB), total bilirubin (TBIL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were markedly decreased in the observation group when contrasted with the control group. Additionally, the levels of vascular endothelial growth factor (VEGF), alpha-fetoprotein (AFP), and tumor-specific growth factor (TSCF) in the observation group were also significantly reduced compared to the control group. Post-treatment, enhancements were observed across all domains of the European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire-30(EORTC QLQ-C30) in both patient cohorts, albeit with the observation group demonstrating statistically significant superior improvements compared to the control group. There was no statistically significant difference in the incidence of adverse reactions between the two groups. Conclusion To treat patients with primary hepatocellular carcinoma, huazhuxin capsule and sorafenib have better efficacy, which helps to improve patients' liver function indexes, reduce the level of tumor markers, and improve patients' quality of life, without increasing the risk of adverse reactions.
关键词
华蟾素胶囊 /
索拉非尼 /
肝细胞癌 /
临床疗效
Key words
toadstool capsules /
sorafenib /
primary hepatocellular carcinoma /
clinical efficacy
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 张龙, 王海溥, 沈裕厚, 等. 高压氧辅助治疗对改善原发性肝癌患者TACE后不良反应及生活质量的作用观察[J]. 中华航海医学与高气压医学杂志, 2023, 30(6): 750-754.
[2] 陈钰, 陈斌斌, 赵静, 等. MRI联合血清AFP-L3和VEGF水平预测TACE术治疗的原发性肝癌患者预后的价值[J]. 实用肝脏病杂志, 2023, 26(4): 556-559.
[3] 李梅, 孙海凤, 程媛, 等. 血清AFP-L3, VEGF表达与原发性肝癌患者TACE治疗预后的相关性[J]. 现代消化及介入诊疗, 2023, 28(2): 237-240.
[4] 石磊, 郝建梅, 杭嘉敏, 等. 白莲化癖汤对原发性肝癌TACE术后患者VEGF、肝功能及AFP-L3表达水平的影响[J]. 海南医学, 2021, 32(3): 278-281.
[5] 曹晓强, 高颢瑾, 杨大干. 基于常规检验数据的原发性肝癌风险预测模型的建立与评价[J]. 临床检验杂志, 2023, 41(8): 575-580.
[6] 朱小东, 周俭. 原发性肝癌新辅助治疗的共识与争议[J]. 中国实用外科杂志, 2023, 43(3): 286-290.
[7] WU Q, GE XL, GENG ZK, et al.HuaChanSu suppresses the growth of hepatocellular carcinoma cells by interfering with pentose phosphate pathway through down-regulation of G6PD enzyme activity and expression[J]. Heliyon, 2024, 10(3): e25144.
[8] 王颖栋, 丁海斌, 黄子超, 等. 华蟾素联合仑伐替尼治疗经动脉化疗栓塞术后原发性肝癌患者的近期疗效[J]. 医学临床研究, 2022, 39(1): 9-12.
[9] 《原发性肝癌诊疗指南 (2024年版) 》编写专家委员会, 周俭. 原发性肝癌诊疗指南 (2024年版)[J]. 中国临床医学, 2024, 31(2): 277-334.
[10] GUIU B, GARIN E, ALLIMANT C, et al.TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC[J]. Cardiovasc Intervent Radiol, 2022, 45(11): 1599-1607.
[11] CHENG AL, QIN S, IKEDA M, et al.Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76(4): 862-873.
[12] WINKELMANN C, MEZENTSEVA A, VOGT B, et al.Patient-Reported Outcome Measures in Liver and Gastrointestinal Cancer Randomized Controlled Trials[J]. Int J Environ Res Public Health, 2023, 20(13): 6293.
[13] 张世斌. 中西医结合治疗老年中晚期肝癌的效果[J]. 中国医学创新, 2023, 20(3): 124-127.
[14] 孙媛, 罗建梅, 米晶晶. 紫杉醇联合索拉非尼治疗原发性肝癌的近远期疗效[J]. 癌症进展, 2022, 20(15): 1601-1603
[15] 胡薪蕊, 吴熙, 殷玉琨, 等. α-干扰素联合索拉菲尼对肝癌细胞增殖的抑制作用及其对STAT3通路的影响[J]. 陕西医学杂志, 2024, 53(10): 1309-1313.
[16] 陈华蕾, 李威. 原发性肝癌治疗中索拉非尼耐药发生机制的研究进展[J]. 肿瘤, 2021, 41(6): 435-443.
[17] 蒋妮, 钟鹏禹, 李敏, 等. 肝动脉灌注化疗对比索拉非尼治疗晚期肝细胞癌有效性和安全性的系统评价[J]. 中国循证医学杂志, 2022, 22(8): 901-907.
[18] 袁福建, 赖小强, 黄少鹏. 华蟾素胶囊联合介入治疗肝癌临床疗效观察[J]. 实用中西医结合临床, 2021, 21(16): 83-84.
[19] 董星宇, 朱婷, 李白坤, 等. 华蟾素对肝癌炎症微环境中HUVEC血管生成的调控作用[J]. 中国药理学通报, 2022, 38(3): 354-359.
[20] HUANG CY, CHENG YM, LI W, et al.Examining the Mechanisms of Huachansu Injection on Liver Cancer through Integrated Bioinformatics Analysis[J]. Recent Pat Anticancer Drug Discov, 2023, 18(3): 408-425.
[21] 任思思, 范妤, 郭东艳, 等. 华蟾素注射液联合西医疗法治疗肝癌有效性与安全性的系统评价Meta分析[J]. 海南医学院学报, 2023, 29(6): 452-462.
[22] 孙志刚, 李佳, 焦勤书, 等. 动脉置管灌注华蟾素注射液联合索拉非尼治疗经动脉化疗栓塞术后原发性肝癌患者近期疗效观察[J]. 中华中医药学刊, 2022, 40(05): 223-226.
[23] 颜根霞, 沈预程, 陆滢滢. AFP-L3和TSGF水平对中晚期原发性肝癌行TACE联合RFA治疗的疗效和预后评估的价值[J]. 胃肠病学和肝病学杂志, 2023, 32(2): 197-201.
[24] PALMIERI VO, SANTOVITO D, MARGARI F, et al.Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis[J]. Clin Exp Med, 2015, 15(1): 65-72.
[25] 张伟. 华蟾素对TACE术治疗肝细胞肝癌后肝内复发和血清VEGF/TSGF表达的影响[J]. 辽宁中医杂志, 2022, 49(12): 72-75.
基金
湖南省自然科学基金青年基金项目“健脾消癌方干预结直肠癌肝转移状态中NLRP3炎症小体介导的Kupffer细胞焦亡的研究”（2021JJ40316）
PDF(2189 KB)
